# Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

> **NCT01154114** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** darapladib

## Key facts

- **NCT ID:** NCT01154114
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-01
- **Primary completion:** 2010-10-15
- **Final completion:** 2010-10-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154114, "Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01154114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*